RJFSA
BBIO icon

Raymond James Financial Services Advisors’s BridgeBio Pharma BBIO Stock Holding History

Raymond James Financial Services Advisors’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-10,816
Closed -$666K – 3314
2021
Q1 		$666K Sell
10,816
-124
-1% -$8.11K ﹤0.01% 2102
2020
Q4 		$778K Buy
10,940
+3,576
+49% +$173K ﹤0.01% 1865
2020
Q3 		$276K Buy
+7,364
New +$232K ﹤0.01% 2323

Other funds holding BBIO

KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
AIG
American International Group New York $2.93M AUM 12.08% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Raymond James Financial Services Advisors's BBIO Position: Q2 2021 in Review

Raymond James Financial Services Advisors sold out of BridgeBio Pharma (BBIO) in Q2 2021, closing a stake of 10,816 shares — an estimated $666K sold.

Raymond James Financial Services Advisors first reported a position in BBIO in Q3 2020 and held it in 3 quarters. The position peaked at $778K in Q4 2020. 201 funds tracked by Wall St. Rank hold BBIO as of Q2 2021.

  • Raymond James Financial Services Advisors reported no remaining BridgeBio Pharma position as of Q2 2021 after selling out during the quarter.
  • Raymond James Financial Services Advisors sold 10,816 BridgeBio Pharma shares in Q2 2021, an estimated $666K.
  • Raymond James Financial Services Advisors first reported a position in BridgeBio Pharma in Q3 2020 and held it in 3 quarters.
  • Raymond James Financial Services Advisors's BridgeBio Pharma position peaked at $778K in Q4 2020.
  • 201 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2021.

Based on Raymond James Financial Services Advisors's 13F filing for Q2 2021, filed 11 Aug 2021.